TECIA法体外药敏试验对食管癌术后化疗个体化方案选择的研究  

Study on the Chemosensitivity Test in Vitro with TECIA in Determining Individualized Chemotherapy for Esophageal Cancer Patients after Surgery

作　　者：张曦[1,2] 党诚学[1] 雷光焰 宋养荣 刘志刚 

机构地区：[1]西安交通大学第一附属医院肿瘤科,陕西西安710061 [2]陕西省肿瘤医院胸外科,陕西西安710061

出　　处：《现代生物医学进展》2013年第26期5037-5040,共4页Progress in Modern Biomedicine

基　　金：陕西省卫生厅科学研究基金项目(08E02)

摘　　要：目的:通过实体瘤体外药敏试验以期指导食管癌术后化疗方案的选择,实现食管癌化疗个体化用药。方法:采用TECIA法对319例肿瘤组织标本进行体外组织培养,并用常见九种化疗药物进行药物敏感性试验,根据试验结果选用化疗方案进行术后辅助化疗。结果:319份标本对常见化疗药高敏感占2.4%,中敏感占48.6%;传统化疗方案药物部分呈现低度敏感,甚至耐药现象;根据药敏结果选用中、高敏感药物进行术后化疗其5年生存期明显延长,复发率降低。结论:肿瘤药物敏感试验对指导患者的个体化治疗具有重要的价值。Objective： To study the effect of chemosensitivity test in vitro so as to provide guidance in choosing individual chemotherapy for patients with Esophageal cancer. Methods： The sensitivity of 319 Esophageal cancer samples to 9 commonly-used chemotherapeutic drugs was determined by TECIA method. Then according to the test results select proper chemotherapy. Results： Of the 319 cases, 2.4% of them were highly sensitive to commonly-used chemotherapeutic drugs, 48.6% of them were moderately sensitive. Some traditional chemotherapeutic drugs appeared lowly sensitive, even resistant. The 5-year survival was significantly prolonged and recurrence rate was decreased after treating with drug of mediurn/hyper sensitivity. Conclusion： The chemosensitivity test in vitro has important value to determine the individualized chemotherapy.

关 键 词：食管癌 药敏 化疗方案选择 

分 类 号：R735.1[医药卫生—肿瘤]